The Centers for Disease Control and Prevention intends to award a modification to existing contract 75D30123D16111 to Sanofi Pasteur Inc. for the purchase of doses of Nirsevimab, Sanofi Pasteur’s RSV vaccine. Nirsevimab is the only product currently licensed by the Food and Drug Administration for prevention of RSV in infants, and Sanofi Pasteur is the only manufacturer of Nirsevimab. This contract action is for supplies or services for which the Government intends to solicit and negotiate with only one source under the authority of FAR 6.302-1 and 41 U.S.C. 3304(a)(1). Interested persons may identify their interest and capability to respond to the requirement or submit proposals.

This notice of intent is not a request for competitive quotations; however, all quotations/responses by November 9, 2023 will be considered by the government.  A determination by the government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the government.  Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement.  Any quotation/response should be emailed to contract specialist William O’Bryan at [email protected] by 5:00 PM EST on November 9, 2023.